Cannabinoid Augmentation of Fear Response in Humans
- Registration Number
- NCT01665573
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this double blind, randomized, controlled, proof-of-concept study is to test the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On three days over not more than two weeks, subjects will be trained to associate cues with two different stimuli, then this association will be extinguished. Cannabinoid receptor stimulation will be accomplished indirectly by harnessing the brain's capacity to endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845. Some details of this study have not been disclosed to preserve the study design.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
- Between the ages of 18 and 65
- Male and female
- No major medical problems
- Hearing problems
- Psychiatric or mental problems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-04457845 Placebo Acquisition of conditioning Administration of drug Extinction of conditioning Placebo Placebo Placebo PF-04457845 PF-04457845 Acquisition of conditioning Administration of drug Extinction of conditioning Placebo PF-04457845 Placebo
- Primary Outcome Measures
Name Time Method Galvanic skin response Test days #1, #2, and #3, on average a week Measure of sympathetic autonomic activation
Cortisol levels measured in blood Test days #1, #2, and #3, on average a week Salivary b-amylase and serum cortisol levels will be assessed as neurochemical measures of stress response.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
VA Connecticut Healthcare System
🇺🇸West Haven, Connecticut, United States